Editing Inclusion body myositis (section)

==Management==
There is no standard course of treatment to slow or stop the progression of the disease as of 2019.<ref name="Weihl2019Review" /> sIBM patients do not reliably respond to [[anti-inflammatory]], [[immunosuppressant]], or [[immunomodulatory | immunomodulatory medications]].<ref>{{Cite journal |last1=Suzuki |first1=Naoki |last2=Mori-Yoshimura |first2=Madoka |last3=Yamashita |first3=Satoshi |last4=Nakano |first4=Satoshi |last5=Murata |first5=Ken-ya |last6=Inamori |first6=Yukie |last7=Matsui |first7=Naoko |last8=Kimura |first8=En |last9=Kusaka |first9=Hirofumi |last10=Kondo |first10=Tomoyoshi |last11=Higuchi |first11=Itsuro |last12=Kaji |first12=Ryuji |last13=Tateyama |first13=Maki |last14=Izumi |first14=Rumiko |last15=Ono |first15=Hiroya |date=2016-11-08 |title=Multicenter questionnaire survey for sporadic inclusion body myositis in Japan |journal=Orphanet Journal of Rare Diseases |language=en |volume=11 |issue=1 |page=146 |doi=10.1186/s13023-016-0524-x |pmid=27821140 |pmc=5100251 |issn=1750-1172 |doi-access=free }}</ref> Most of disease management is [[Symptomatic treatment|supportive care]].<ref name="Weihl2019Review" /> Prevention of falls is an important consideration.<ref name="Weihl2019Review" /> There is no consensus on [[Exercise therapy for idiopathic inflammatory myopathies|exercise guidelines]]; however, physical therapy is recommended to teach the patient a home exercise program, to teach how to compensate during mobility-gait training with an assistive device, transfers and bed mobility.<ref>{{Cite web|date=March 17, 2019|title=Inclusion Body Myositis Information Page|url=https://www.ninds.nih.gov/Disorders/All-Disorders/Inclusion-Body-Myositis-Information-Page|access-date=June 25, 2021|website=National Institute of Neurological Disorders and Stroke}}</ref> An exercise regimen preferentially minimizes a patient's risk of injury and corresponds to the patient's goals.<ref name="Weihl2019Review" /><ref>{{Cite journal |last1=Naddaf |first1=Elie |last2=Barohn |first2=Richard J. |last3=Dimachkie |first3=Mazen M. |date=August 22, 2018 |title=Inclusion Body Myositis: Update on Pathogenesis and Treatment |journal=Neurotherapeutics |volume=15 |issue=4 |pages=995–1005 |doi=10.1007/s13311-018-0658-8 |issn=1933-7213 |pmc=6277289 |pmid=30136253}}</ref>